| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 2.1 |
| Net income | -33.5 | -20.2 |
| EPS (diluted, $ a share) | $-0.73 | $-0.56 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -85.5% |
|---|
10-Q filed with the SEC, NASDAQ: BIOA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
BioAge Labs, Inc.: key numbers
- Share price
- $5.22Close, Nov 16
- Market cap
- $240M
- Shares outstanding
- 45.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BioAge Labs, Inc.
All →BioAge Labs Financial Results
BioAge Labs reported third quarter 2026 financial results, highlighting the dosing of the first participant in its Phase 2 QUELL-DME trial for diabetic macular edema. The company also completed enrollment in its Phase 2 QUELL-CV trial for obesity and inflammation, with topline data expected in Q4 2026.
- Term
- Q3 2026
“NLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6, are already approved for multiple indications, but a once-daily pill that works earlier in the process—and also lowers IL-18 and reduces harmful inflammatory cell death—could help many more people. That is the opportunity we are pursuing with BGE-102.”
Kristen Fortney, Ph.D., CEO and co-founder of BioAge
BioAge Labs Clinical Trial Data
BioAge Labs announced the first participant has been dosed in its QUELL-DME Phase 2 clinical trial evaluating BGE-102, an oral NLRP3 inhibitor, for the treatment of diabetic macular edema. The 180-participant trial will evaluate the drug as both a monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.